IF 1.6 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS
Akihiro Tobe, Patrick Serruys, Kotaro Miyashita, Asahi Oshima, Pruthvi Chenniganahosahalli Revaiah, Tsung-Ying Tsai, Dijkstra Jouke, Scot Garg, Angela McInerney, Yoshinobu Onuma, Faisal Sharif
{"title":"Serial quantitative optical coherence tomography for luminal volume changes following either paclitaxel or sirolimus coated balloon in de novo small coronary artery lesions.","authors":"Akihiro Tobe, Patrick Serruys, Kotaro Miyashita, Asahi Oshima, Pruthvi Chenniganahosahalli Revaiah, Tsung-Ying Tsai, Dijkstra Jouke, Scot Garg, Angela McInerney, Yoshinobu Onuma, Faisal Sharif","doi":"10.1016/j.carrev.2025.03.025","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Drug coated balloons (DCB) are a treatment option for lesions in small coronary arteries, with treatment using paclitaxel coated balloons (PCB) associated with less angiographic late lumen loss than sirolimus coated balloons (SCB).</p><p><strong>Methods: </strong>This single-center sub-study of the TRANSFORM-I study compared quantitative optical coherence tomography (OCT) data in patients with de novo lesions in small coronary arteries treated with the MagicTouch (SCB) or SeQuent Please Neo (PCB). The relationship between the lumen volume of the treated segment immediately post procedure and at 6-month follow-up was evaluated. Late lumen volume loss (LLVL, mm<sup>3</sup>) was defined as the post-procedural lumen volume - lumen volume at 6 months.</p><p><strong>Results: </strong>Serial OCT analysis was performed in 19 patients with 21 lesions (SCB: 9 patients/11 lesions; PCB: 10 patients/10 lesions). There was a significant decrease in lumen volume between post-procedure and 6 months in the SCB group (97.35 ± 71.09 mm<sup>3</sup> vs 87.96 ± 61.48 mm<sup>3</sup>, p = 0.03), but not in the PCB group (69.67 ± 38.24 mm3 vs 71.64 ± 42.22 mm3, p = 0.64). The LLVL was 9.39 ± 12.76 mm<sup>3</sup> and - 1.97 ± 12.90 mm<sup>3</sup> in the SCB and PCB group, respectively (SCB vs PCB, p = 0.06). A trend for interaction between SCB and PCB was observed in the relationship between dissection volume and LLVL (SCB: LLVL = 1.28 ∗ dissection volume + 7.42, p = 0.37; PCB: LLVL = -2.84 ∗ dissection volume + 4.51, p = 0.12; p for interaction = 0.07).</p><p><strong>Conclusion: </strong>In de novo lesions of small coronary arteries, treatment with an SCB lead to a significant decrease in lumen volume at 6-months compared to post-procedure, with no significant change observed after treatment with a PCB.</p>","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":" ","pages":""},"PeriodicalIF":1.6000,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiovascular Revascularization Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.carrev.2025.03.025","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

摘要

背景:药物涂层球囊(DCB)是治疗冠状动脉小动脉病变的一种选择,与西罗莫司涂层球囊(SCB)相比,使用紫杉醇涂层球囊(PCB)治疗血管造影晚期管腔损失较少:这项 TRANSFORM-I 研究的单中心子研究比较了使用 MagicTouch(SCB)或 SeQuent Please Neo(PCB)治疗小冠状动脉新发病变患者的定量光学相干断层扫描(OCT)数据。评估了术后即刻和随访 6 个月时治疗段管腔容积之间的关系。晚期管腔容积损失(LLVL,mm3)被定义为术后管腔容积-6个月时的管腔容积:对 19 名患者的 21 个病灶(SCB:9 名患者/11 个病灶;PCB:10 名患者/10 个病灶)进行了序列 OCT 分析。SCB 组的管腔容积在手术后至 6 个月期间明显减少(97.35 ± 71.09 mm3 vs 87.96 ± 61.48 mm3,p = 0.03),但 PCB 组没有明显减少(69.67 ± 38.24 mm3 vs 71.64 ± 42.22 mm3,p = 0.64)。SCB 组和 PCB 组的 LLVL 分别为 9.39 ± 12.76 mm3 和 - 1.97 ± 12.90 mm3(SCB vs PCB,p = 0.06)。在夹层容积与 LLVL 的关系中,观察到 SCB 和 PCB 之间存在相互作用的趋势(SCB:LLVL = 1.28 ∗ 夹层容积 + 7.42,p = 0.37;PCB:LLVL = -2.84 ∗ 夹层容积 + 4.51,p = 0.12;相互作用的 p = 0.07):结论:对于小冠状动脉的新发病变,使用 SCB 治疗后,6 个月后的管腔容积与手术后相比明显减少,而使用 PCB 治疗后则没有观察到明显变化。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Serial quantitative optical coherence tomography for luminal volume changes following either paclitaxel or sirolimus coated balloon in de novo small coronary artery lesions.

Background: Drug coated balloons (DCB) are a treatment option for lesions in small coronary arteries, with treatment using paclitaxel coated balloons (PCB) associated with less angiographic late lumen loss than sirolimus coated balloons (SCB).

Methods: This single-center sub-study of the TRANSFORM-I study compared quantitative optical coherence tomography (OCT) data in patients with de novo lesions in small coronary arteries treated with the MagicTouch (SCB) or SeQuent Please Neo (PCB). The relationship between the lumen volume of the treated segment immediately post procedure and at 6-month follow-up was evaluated. Late lumen volume loss (LLVL, mm3) was defined as the post-procedural lumen volume - lumen volume at 6 months.

Results: Serial OCT analysis was performed in 19 patients with 21 lesions (SCB: 9 patients/11 lesions; PCB: 10 patients/10 lesions). There was a significant decrease in lumen volume between post-procedure and 6 months in the SCB group (97.35 ± 71.09 mm3 vs 87.96 ± 61.48 mm3, p = 0.03), but not in the PCB group (69.67 ± 38.24 mm3 vs 71.64 ± 42.22 mm3, p = 0.64). The LLVL was 9.39 ± 12.76 mm3 and - 1.97 ± 12.90 mm3 in the SCB and PCB group, respectively (SCB vs PCB, p = 0.06). A trend for interaction between SCB and PCB was observed in the relationship between dissection volume and LLVL (SCB: LLVL = 1.28 ∗ dissection volume + 7.42, p = 0.37; PCB: LLVL = -2.84 ∗ dissection volume + 4.51, p = 0.12; p for interaction = 0.07).

Conclusion: In de novo lesions of small coronary arteries, treatment with an SCB lead to a significant decrease in lumen volume at 6-months compared to post-procedure, with no significant change observed after treatment with a PCB.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Cardiovascular Revascularization Medicine
Cardiovascular Revascularization Medicine CARDIAC & CARDIOVASCULAR SYSTEMS-
CiteScore
3.30
自引率
5.90%
发文量
687
审稿时长
36 days
期刊介绍: Cardiovascular Revascularization Medicine (CRM) is an international and multidisciplinary journal that publishes original laboratory and clinical investigations related to revascularization therapies in cardiovascular medicine. Cardiovascular Revascularization Medicine publishes articles related to preclinical work and molecular interventions, including angiogenesis, cell therapy, pharmacological interventions, restenosis management, and prevention, including experiments conducted in human subjects, in laboratory animals, and in vitro. Specific areas of interest include percutaneous angioplasty in coronary and peripheral arteries, intervention in structural heart disease, cardiovascular surgery, etc.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信